Previous 10 | Next 10 |
Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening of Live Training Facility, Expansion of Marketing Programs, Additional FDA Approval and Positive Study Results Management to Host Co...
Small and Micro-cap investors are invited to attend the Q4 Investor Summit being held on November 16-17, 2021. The event is organized by the Investor Summit Group, recognised as a highly reputed brand for hosting North America’s largest independent investor conferences. Over 90 pre...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep apnea (“OSA”), will be presenting at the upcoming Q4 Virtual Investor Summit. The sum...
HIGHLANDS RANCH, Colo., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“the Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative treatments for patients suffering from mild-to-moderate obstructive sleep a...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring in adults, today announced that it...
HIGHLANDS RANCH, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients s...
A new study has discovered a link between triglycerides and obstructive sleep apnea ("OSA"). Triglycerides are a type of lipid in the blood that gives energy to an individual�s body. High triglyceride levels raise an individual�s risk of pancreatitis, strokes and heart attac...
The National Institutes of Health estimates that about 25 million individuals in America suffer from obstructive sleep apnea. Obstructive sleep apnea is a common sleep disorder that causes an individual’s breathing to start and stop while they’re asleep. The disorder affects ...
Vivos Therapeutics (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (“OSA”) and snoring, today announced that its chairman...
HIGHLANDS RANCH, Colo., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS) , a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients s...
News, Short Squeeze, Breakout and More Instantly...
Vivos Therapeutics Inc. Company Name:
VVOS Stock Symbol:
NASDAQ Market:
Vivos Therapeutics Inc. Website:
LITTLETON, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company” (NASDAQ:VVOS) , a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments f...
Vivos Therapeutics (NASDAQ: VVOS) is a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (“OSA”) i...
Alliance with Sleep Treatment Provider in Colorado Marks Critical Pivot in Vivos’ Marketing and Distribution Model Aimed at Enhancing Revenue Streams and Potential Profit Private Placement Investment Sponsored by Seneca Partners, Who Will Also Provide General Management Advisory ...